Correction to: Scientific Reports https://doi.org/10.1038/s41598-025-90508-z, published online 06 March 2025
This original version of this Article contained errors. At the time of the preparation of this manuscript, the Authors were working on a separate manuscript. As a result of an error during the editing process, text from the Conclusion section of the other paper was used in the Conclusion section of this Article. This has now been updated and the Conclusion section,
“It appears that this is the first meta-analysis to investigate the impact of checkpoint inhibitor treatment (Anti-PD1, Anti-CTLA4) on the level of T-lymphocyte (CD4+, CD8+). Our study found that the response or nonresponse to checkpoint inhibitor treatment in melanoma patients is correlated with the level of T-lymphocyte (CD4+, CD8+). Furthermore, in a melanoma mouse model, tumor volume and survival were found to be linked to T-lymphocyte (CD4+, CD8+) levels following checkpoint inhibitor treatment. These findings may aid researchers in selecting a more appropriate treatment protocol when dealing with melanoma. Our findings demonstrate that the combination of CAP and DOX produces synergistic effects on reducing melanoma cell viability and increasing cytotoxicity. These effects are likely mediated through mechanisms such as enhanced oxidative stress and DNA damage. However, the reliance on in vitro data underscores the need for additional research in vivo and clinical settings to validate these findings.”
now reads:
“Our findings demonstrate that the combination of cold atmospheric plasma (CAP) and doxorubicin (DOX) produces synergistic effects in reducing melanoma cell viability and increasing cytotoxicity compared to either treatment alone. These effects are likely mediated through mechanisms such as enhanced oxidative stress and DNA damage. However, the reliance on in vitro data underscores the need for further in vivo and clinical research to validate these results and to explore the therapeutic potential of this combination in melanoma treatment.”
The original Article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Rostami, Z., Alizadeh-Navaei, R., Golpoor, M. et al. Author Correction: Synergistic effects of cold atmospheric plasma and doxorubicin on melanoma: A systematic review and meta-analysis. Sci Rep 15, 38513 (2025). https://doi.org/10.1038/s41598-025-26577-x
Published:
Version of record:
DOI: https://doi.org/10.1038/s41598-025-26577-x